威尼斯人
奥比努图库单抗
医学
伊布替尼
慢性淋巴细胞白血病
内科学
肿瘤科
临床试验
药理学
苯达莫司汀
淋巴瘤
化疗
作者
Mazyar Shadman,Keri Yang,Sheng Xu,Rhys Williams,Talha Munir
标识
DOI:10.1080/10428194.2026.2722721
摘要
No head-to-head studies have compared continuous zanubrutinib monotherapy and fixed-duration acalabrutinib plus venetoclax (AV) or venetoclax plus obinutuzumab (VenO) in treatment-naïve patients with low-risk (no del[17p]/TP53 mutations) chronic lymphocytic leukemia (CLL). Herein, a network meta-analysis (NMA) estimated the relative efficacy of these regimens (zanubrutinib: SEQUOIA; AV: AMPLIFY; VenO: GAIA/CLL13). Investigator-assessed progression-free survival (PFS-INV) was compared, with relative effects reported as hazard ratio (HR) with 95% credible interval (CrI). In the base case, zanubrutinib had favorable PFS-INV versus AV (HR 0.46 [95% CrI: 0.28–0.76]) and VenO (HR 0.63 [0.35–1.14]). PFS was also favorable for zanubrutinib in IGHV unmutated (vs. AV: HR 0.30 [0.16–0.58]; vs. VenO: HR 0.56 [0.27–1.15]) and mutated (vs. AV: HR 0.49 [0.21–1.13]; vs. VenO: HR 0.54 [0.17–1.68]) subgroups. While interpretation requires caution considering the limitations inherent to NMAs, the data demonstrate improved PFS with continuous zanubrutinib monotherapy versus fixed-duration AV or VenO for treatment-naïve patients with low-risk CLL.Trial registration numbers SEQUOIA, NCT03336333; AMPLIFY, NCT03836261; GAIA/CLL13, NCT02950051.
科研通智能强力驱动
Strongly Powered by AbleSci AI